Investigation of two novel biochemical markers of inflammation, matrix metalloproteinase and cathepsin generated fragments of C-reactive protein, in patients with ankylosing spondylitis

Clinical and Experimental Rheumatology

Volumn 30, Issue 3, 2012, Pages 371-379

  Skjøt Arkil, Helene ^a,b   Schett, Georg ^c   Zhang, Chen ^a   Larsen, Dorthe Vang ^a   Wang, Yaguo ^b   Zheng, Qinlong ^d   Larsen, Martin Røssel ^e   Nawrocki, Arkadiusz ^e   Bay Jensen, Anne Christine ^a   Henriksen, Kim ^a   Christiansen, Claus ^a   Alexandersen, Peter ^f   Leeming, Diana Julie ^a   Karsdal, Morten Asser ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d Nordic Bioscience Beijing   (China)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^f CCBR   (Denmark)

Author keywords

Ankylosing spondylitis; Biomarker; C reactive protein; Inflammation; Neoepitope

Indexed keywords

C REACTIVE PROTEIN; CATHEPSIN; MATRIX METALLOPROTEINASE;

ADULT; AGED; ANIMAL EXPERIMENT; ANKYLOSING SPONDYLITIS; ARTICLE; BATH OF ANKYLOSING SPONDYLITIS ACTIVITY INDEX; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; STROKE ANKYLOSING SPONDYLITIS SPINE SCORE;

AGED; AMINO ACID SEQUENCE; ANIMALS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CATHEPSINS; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HUMANS; INFLAMMATION; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED BALB C; MIDDLE AGED; PEPTIDE FRAGMENTS; ROC CURVE; SPONDYLITIS, ANKYLOSING;

EID: 84864778747     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Volanakis JE: Human C-reactive protein: expression, structure, and function. Mol Immunol 2001; 38: 189-97.
2. Du Clos TW: Function of C-reactive protein. Ann Med 2000; 32: 274-8.
3. Hirschfield GM, Pepys MB: C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM 2003; 96: 793-807.
4. Clutterbuck AL, Asplin KE, Harris P, Allaway D, Mobasheri A: Targeting matrix metalloproteinases in inflammatory conditions. Curr Drug Targets 2009; 10: 1245-54.
5. Skjot-Arkil H, Barascuk N, Register T, Karsdal MA: Macrophage-mediated proteolytic remodeling of the extracellular matrix in atherosclerosis results in neoepitopes: a potential new class of biochemical markers. Assay Drug Dev Technol 2010; 8: 542-52.
6. Zhen EY, Brittain IJ, Laska DA et al.: Characterization of metalloprotease cleavage products of human articular cartilage. Arthritis Rheum 2008; 58: 2420-31.
7. Yoshida W, Uzuki M, Nishida J, Shimamura T, Sawai T: Examination of in vivo gelatinolytic activity in rheumatoid arthritis synovial tissue using newly developed in situ zymography and image analyzer. Clin Exp Rheumatol 2009; 27: 587-93.
8. Hamzaoui K, Maitre B, Hamzaoui A: Elevated levels of MMP-9 and TIMP-1 in the cerebrospinal fluid of neuro-Behçet's disease. Clin Exp Rheumatol 2009; 27 (Suppl. 53): S52-S57.
9. Koskinen A, Vuolteenaho K, Nieminen R, Moilanen T, Moilanen E: Leptin enhances MMP-1, MMP-3 and MMP-13 production in human osteoarthritic cartilage and correlates with MMP-1 and MMP-3 in synovial fluid from OA patients. Clin Exp Rheumatol 2011; 29: 57-64.
10. Milner JM, Cawston TE: Matrix metalloproteinase knockout studies and the potential use of matrix metalloproteinase inhibitors in the rheumatic diseases. Curr Drug Targets Inflamm Allergy 2005; 4: 363-75.
11. Karsdal MA, Henriksen K, Leeming DJ et al.: Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 2009; 14: 181-202.
12. Lochter A, Bissell MJ: An odyssey from breast to bone: multi-step control of mammary metastases and osteolysis by matrix metalloproteinases. APMIS 1999; 107: 128-36.
13. Karsdal MA, Madsen SH, Christiansen C, Henriksen K, Fosang AJ, Sondergaard BC: Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther 2008; 10: R63.
14. Veidal SS, Vassiliadis E, Barascuk N et al.: Matrix metalloproteinase-9-mediated type III collagen degradation as a novel serological biochemical marker for liver fibrogenesis. Liver Int 2010; 30: 1293-304.
15. Barascuk N, Veidal SS, Larsen L et al.: A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neoepitope of type III collagen. Clin Biochem 2010; 43: 899-904.
16. Bay-Jensen AC, Liu Q, Byrjalsen I et al.: Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM-Increased serum CIIM in subjects with severe radiographic osteoarthritis. Clin Biochem 2011; 44: 423-9.
17. Tam LS, Gu J, Yu D: Pathogenesis of ankylosing spondylitis. Nat Rev Rheumatol 2010; 6: 399-405.
18. De Vlam K: Soluble and tissue biomarkers in ankylosing spondylitis. Best Pract Res Clin Rheumatol 2010; 24: 671-82.
19. Conrozier T, Poole AR, Ferrand F et al.: Serum concentrations of type II collagen biomarkers (C2C, C1, 2C and CPII) suggest different pathophysiologies in patients with hip osteoarthritis. Clin Exp Rheumatol 2008; 26: 430-5.
20. Kempta LF, Piette JC, Bastuji-Garin S et al.: Serum cartilage oligomeric matrix protein (COMP) level is a marker of disease activity in relapsing polychondritis. Clin Exp Rheumatol 2010; 28: 553-5.
21. Muntean L, Rojas-Vargas M, Font P et al.: Relative value of the lumbar spine and hip bone mineral density and bone turnover markers in men with ankylosing spondylitis. Clin Rheumatol 2011; 30: 691-5.
22. Pinzone JJ, Hall BM, Thudi NK et al.: The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 2009; 113: 517-25.
23. Appel H, Ruiz-Heiland G, Listing J et al.: Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009; 60: 3257-62.
24. Garnero P, Ferreras M, Karsdal MA et al.: The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003; 18: 859-67.
25. Karsdal MA, Henriksen K, Leeming DJ, Woodworth T, Vassiliadis E, Bay-Jensen AC: Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers--are they the cause or the consequence of the disease? Clin Biochem 2010; 43: 793-804.
26. Karsdal MA, Woodworth T, Henriksen K et al.: Biochemical markers of ongoing joint damage in rheumatoid arthritis - current and future applications, limitations and opportunities. Arthritis Res Ther 2011; 13: 215.
27. Karsdal MA, Delvin E, Christiansen C: Protein fingerprints - Relying on and understanding the information of serological protein measurements. Clin Biochem 2011; 44: 1278-9.
28. Thingholm TE, Larsen MR: The use of titanium dioxide micro-columns to selectively isolate phosphopeptides from proteolytic digests. Methods Mol Biol 2009; 527: 57-66, xi.
29. Combet C, Blanchet C, Geourjon C, Deleage G: NPS@: network protein sequence analysis. Trends Biochem Sci 2000; 25: 147-50.
30. Gefter ML, Margulies DH, Scharff MD: A simple method for polyethylene glycolpromoted hybridization of mouse myeloma cells. Somatic Cell Genet 1977; 3: 231-6.
31. Chen CH, Lin KC, Yu DT et al.: Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford) 2006; 45: 414-20.
32. Wendling D, Cedoz JP, Racadot E: Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNF-alpha antagonist therapy. Joint Bone Spine 2008; 75: 559-62.
33. Shiozawa S, Tsumiyama K, Yoshida K, Hashiramoto A: Pathogenesis Of Joint Destruction In Rheumatoid Arthritis. Arch Immunol Ther Exp (Warsz) 2011; 59: 89-95.
34. Schurigt U, Stopfel N, Huckel M, Pfirschke C, Wiederanders B, Brauer R: Local expression of matrix metalloproteinases, cathepsins, and their inhibitors during the development of murine antigen-induced arthritis. Arthritis Res Ther 2005; 7: R174-R188.
35. Barascuk N, Skjot-Arkil H, Register TC et al.: Human macrophage foam cells degrade atherosclerotic plaques through cathepsin K mediated processes. BMC Cardiovasc Disord 2010; 10: 19.
36. Sorensen MG, Henriksen K, Schaller S et al.: Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood. J Bone Miner Metab 2007; 25: 36-45.
37. Ruof J, Stucki G: Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 1999; 26: 966-70.
38. Sheehan NJ, Slavin BM, Donovan MP, Mount JN, Mathews JA: Lack of correlation between clinical disease activity and erythrocyte sedimentation rate, acute phase proteins or protease inhibitors in ankylosing spondylitis. Br J Rheumatol 1986; 25: 171-4.
39. Spoorenberg A, Van Der HD, De Ke et al.: Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999; 26: 980-4.
40. Sondergaard BC, Henriksen K, Wulf H et al.: Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthritis Cartilage 2006; 14: 738-48.
41. Meulenbelt I, Kloppenburg M, Kroon HM et al.: Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study. Ann Rheum Dis 2006; 65: 360-5.
42. Bauer DC, Hunter DJ, Abramson SB et al.: Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 2006; 14: 723-7.
43. Leeming DJ, Larsen DV, Zhang C et al.: Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP)--assessment of corresponding epitopes. Clin Biochem 2010; 43: 1249-56.